Replies to post #16450 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Are you making this up? You have no way of knowing the financial terms of the Amgen deal, which is subject to a CTO. Unless you are claiming to have inside information.

[fbg0316]

I agree with your point on the revenue share, should be much higher for our cervical cancer deal. I still think ADXS should be able to command a sizeable upfront payment as well. Upfront cash is a direct injection of cash on the company balance sheet which will mitigate shareholder dilution. On the point on choosing between diluting revenue on the back end versus shareholder dilution upfront, IMO it's in our interest to try to secure upfront cash because when we're talking about future revenue of our cervical cancer construct in several years the revenue for our monotherapy could diminish if, for example, we get a PD1 approval with Astra on combo regimen. I'm sure that conversation is part of the negotiation, i.e., ADXS will want to get paid upfront for giving Astra rights to establish a market for our monotherapy which will benefit Astra's ability down the road with market penetration already in place for when the combo regimen is approved.

[polaco3us]

If I recall correctly my english lessons
low single digit: between 1 to 3
mid single digit: 4,5,6
high single digit : between 7 to 9
and so it goes for low,mid and high double digits (just put a zero)


Go Zen
Cheers